Proactive Investors - Run By Investors For Investors

Advent International in talks to buy French drugs giant Sanofi's European generics business

The business, Zentiva operates in 50 markets and has a strong presence in Eastern Europe, particularly in the Czech Republic, Slovakia and Romania
Drugs
Zentiva's generic drugs portfolio includes cardiovascular and gastrointestinal drugs as well as painkillers and anti-inflammatory drugs

US private equity firm Advent International Corp. LLP is in exclusive negotiations to buy French drugs giant Sanofi SA’s (NYSE:SNY) European generics business Zentiva for an enterprise value of €1.92bn (US$2.37bn).

In a statement, the French company said Advent had made a firm, binding and fully financed offer.

READ: Takeda’s possible US$50bn Shire bid thrown into doubt as UK pharma sells off oncology unit for US$2.4bn

It added that the transaction is expected to close by the end of 2018, following consultation with Sanofi employees' representatives and regulatory approval.

The sale of the non-core business, which was flagged up back in October, forms part of Sanofi's strategy to simplify the company.

Zentiva operates in 50 markets and has a strong presence in Eastern Europe, particularly in the Czech Republic, Slovakia and Romania.

Its generic drugs portfolio includes cardiovascular and gastrointestinal drugs as well as painkillers and anti-inflammatory drugs based on ibuprofen and leflunomide molecules.

The disposal is the second big move in the drugs sector this week, with UK group Shire Plc (LON:SHP) on Monday announcing plans to sell its oncology business to unlisted French drugmaker Servier for US$2.4bn as it attempts to fend off a possible takeover bid by Japanese giant Takeda.

View full SNY profile View Profile

Sanofi Timeline

Related Articles

Oncoprex
October 17 2018
The biotech was founded by an investment group led by scientists and driven by a no-nonsense CEO whose stake is more than just business as usual
Vial of pills
June 25 2018
Cosmos is a modern company, but the trade routes it relies on are ancient
woman at a microscope
August 02 2018
Currently undergoing phase III clinical trials, AP101 is being developed to treat Epidermolysis Bullosa, a condition which occurs prominently in children and makes skin fragile to even the faintest touch

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use